Zevra Therapeutics (ZVRA) Net Income towards Common Stockholders (2014 - 2026)
Zevra Therapeutics (ZVRA) reported Net Income towards Common Stockholders of $37.9 million for Q1 2026, up 1322.65% on a YoY basis from $2.7 million in Q1 2025, and up 211.47% quarter-over-quarter from $12.2 million in Q4 2025.
Zevra Therapeutics (ZVRA) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Zevra Therapeutics has reported Net Income towards Common Stockholders for 13 years, with the latest figure at $37.9 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 1322.65% year-over-year to $37.9 million; the trailing twelve-month figure through Mar 2026 stood at $124.2 million (up 235.04% YoY), and the FY2025 full-year result was $83.2 million, up 178.88% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at $37.9 million, up from $12.2 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $74.7 million in Q2 2025, with the low at -$35.7 million in Q4 2024.
- Historically, Net Income towards Common Stockholders has averaged -$4.1 million across 5 years, with a median of -$9.0 million in 2022.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders slumped 674.39% — and 2026, when it jumped 1322.65%.
- Zevra Therapeutics' Net Income towards Common Stockholders stood at -$9.0 million in 2022, then sank by 120.51% to -$19.9 million in 2023, then slumped by 79.67% to -$35.7 million in 2024, then soared by 134.04% to $12.2 million in 2025, then jumped by 211.47% to $37.9 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at $37.9 million (Q1 2026), $12.2 million (Q4 2025), and -$544000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Zevra Therapeutics | 787.90 Mn | 587.28 Mn | 34.30 Mn | 37.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.89 Mn |
| Dec 31, 2025 | 12.17 Mn |
| Sep 30, 2025 | -544,000.00 |
| Jun 30, 2025 | 74.71 Mn |
| Mar 31, 2025 | -3.10 Mn |
| Dec 31, 2024 | -35.74 Mn |
| Sep 30, 2024 | -33.23 Mn |
| Jun 30, 2024 | -19.93 Mn |
| Mar 31, 2024 | -16.62 Mn |
| Dec 31, 2023 | -19.89 Mn |
| Sep 30, 2023 | -10.37 Mn |
| Jun 30, 2023 | -2.57 Mn |
| Mar 31, 2023 | -11.77 Mn |
| Dec 31, 2022 | -9.02 Mn |
| Sep 30, 2022 | -6.62 Mn |
| Jun 30, 2022 | -24.04 Mn |
| Mar 31, 2022 | -1.86 Mn |
| Dec 31, 2021 | -2.70 Mn |
| Sep 30, 2021 | -1.76 Mn |
| Jun 30, 2021 | -10.70 Mn |